Epstein Files Search

EFTA01092032Set 9

25p12,760w

hear, the mind believes" — IntellicellBioScience (SVFC)-$0.05 - NR Harry Houdini. In the wake of Pluristem's clinical hold, some Lonw (LONN.VX)- CHF72.30 -NR investors have been asking if there ... safe. Well, that Pfizer (PFE) — $27.97 — NR depends? Were the autologous cells manipulated, enriched, Pluristem (PSTI)— $2.98 - Hold exposed to media, or expanded? The NeoStem product is Tens Pharmaceuticals (TEVA ... misnomer to claim that no manipulation occurs. g so > The clinical hold on Pluristem has become fodder for some who a to want to raise the allo safety question

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf

EFTA00956529Set 9

2013-03-147p5,347w

significant player in RA is very great. What else differentiates Mesoblast from Athersys. Pluristem Therapeutics Inc. (PSTI:NASDAO) orCylorl Therapeutics Inc. (CYTX:NASDACI)? Maybe the single largest differenbator ... OSIR:NASDAO) Prochymal (remestemcel-L). The reality is that the Athersys cell. the Pluristem cell and the Mesoblast cell are all different TLSR: So patent protection begins with the selection ... believe. for acute injury. you want allogeneic models like those being developed by Mesoblast. Pluristem and Athersys. On the other hand. the autologous model. like Cytori's or IntelliCellElioSciences

https://www.justice.gov/epstein/files/DataSet%209/EFTA00956529.pdf

EFTA01092027Set 9

2013-10-125p2,524w

cell therapy space. Pfizer (PFE) — $30.40 — NR Yesterday, Osiris clarified the regulatory status. Pluristem (PSTI) — $3.63 — Buy RTI Biologics (RTIX)— $3.43 — NR > The company announced that it has reached ... criterion. On the other hand, Athersys' MAPC, Mesoblast's mesenchymal precursor cells (MPC), or Pluristem's Placental eXpanded (PLX) cells will not meet this requirement since they are expanded

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092027.pdf

EFTA01092057Set 9

2013-08-165p2,594w

Pfizer (PFE) - $28.80 - NR demonstrated the utility of Grafix, the company's allogeneic product Pluristem (PSTI) - $114 - Hold for diabetic fool ulcers (DFU). long a graveyard of failed therapies ... first criterion. On the other hand, Athersys MAPC, Mesoblasts Messenchymal precursor cells (MPC) or Pluristem's Placental eXpanded (PLX) cells will not meet this requirement since they are expanded

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092057.pdf